Maria Cristina Foss-Freitas

Dr. Maria Cristina Foss-Freitas

orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2007 in JAMA
Verified
Journal Article
Open access
PDF file
JVJúlio C. Voltarelli
Júlio C. Voltarelli
CCCarlos E. B. Couri
Carlos E. B. Couri
ASAna B. P. L. Stracieri
Ana B. P. L. Stracieri
MOMaria C. Oliveira
Maria C. Oliveira
DMDaniela A. Moraes
Daniela A. Moraes
RBRichard Burt
Richard Burt
Type 1 diabetes mellitus (DM) results from a cell-mediated autoimmune attack against pancreatic beta cells.1 The course of autodestruction is subclinical until the amount of beta-cell mass is insufficient to maintain glucose homeostasis. Thus, at the time of clinical diagnosis, approximately 60% to 80% of the beta-cell mass has been destroyed.2

15 April 2009 in JAMA
Verified
Journal Article
Open access
PDF file
CCCarlos E. B. Couri
Carlos E. B. Couri
MOMaria C. B. Oliveira
Maria C. B. Oliveira
ASAna B. P. L. Stracieri
Ana B. P. L. Stracieri
DMDaniela A. Moraes
Daniela A. Moraes
FPFabiano Pieroni
Fabiano Pieroni
JVJúlio C. Voltarelli
Júlio C. Voltarelli
Accumulated clinical experience indicates that there is an inverse association between beta-cell function and chronic complications of type 1 diabetes mellitus (DM)—the higher the C-peptide levels (an indirect measure of viable beta-cell function), the lower the incidence of microvascular complications of type 1 DM.1 Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees.2,3

26 November 2013 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
CCCristhianna Va Collares
Cristhianna Va Collares
AEAdriane Evangelista
Adriane Evangelista
DXDanilo J Xavier
Danilo J Xavier
DRDiane M Rassi
Diane M Rassi
TAThais Arns
Thais Arns
EDEduardo A. Donadi
Eduardo A. Donadi
Background: Regardless the regulatory function of microRNAs (miRNA), their differential expression pattern has been used to define miRNA signatures and to disclose disease biomarkers. To address the question of whether patients presenting the different types of diabetes mellitus could be distinguished on the basis of their miRNA and mRNA expression profiling, we obtained peripheral blood mononuclear cell (PBMC) RNAs from 7 type 1 (T1D), 7 type 2 (T2D), and 6 gestational diabetes (GDM) patients, which were hybridized to Agilent miRNA and mRNA microarrays. Data quantification and quality control were obtained using the Feature Extraction software, and data distribution was normalized using quantile function implemented in the Aroma light package. Differentially expressed miRNAs/mRNAs were identified using Rank products, comparing T1DxGDM, T2DxGDM and T1DxT2D. Hierarchical clustering was performed using the average linkage criterion with Pearson uncentered distance as metrics. Results: The use of the same microarrays platform permitted the identification of sets of shared or specific miRNAs/mRNA interaction for each type of diabetes. Nine miRNAs (hsa-miR-126, hsa-miR-1307, hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-144, hsa-miR-199a-5p, hsa-miR-27a, hsa-miR-29b, and hsa-miR-342-3p) were shared among T1D, T2D and GDM, and additional specific miRNAs were identified for T1D (20 miRNAs), T2D (14) and GDM (19) patients. ROC curves allowed the identification of specific and relevant (greater AUC values) miRNAs for each type of diabetes, including: i) hsa-miR-1274a, hsa-miR-1274b and hsa-let-7f for T1D; ii) hsa-miR-222, hsa-miR-30e and hsa-miR-140-3p for T2D, and iii) hsa-miR-181a and hsa-miR-1268 for GDM. Many of these miRNAs targeted mRNAs associated with diabetes pathogenesis. Conclusions: These results indicate that PBMC can be used as reporter cells to characterize the miRNA expression profiling disclosed by the different diabetes mellitus manifestations. Shared miRNAs may characterize diabetes as a metabolic and inflammatory disorder, whereas specific miRNAs may represent biological markers for each type of diabetes, deserving further attention.

1 May 2008 in Journal of Periodontology
Verified
Journal Article
Closed access
POPatricia A.A. O'Connell
Patricia A.A. O'Connell
Mario Taba JrMario Taba Jr
Mario Taba Jr
ANAuro Nomizo
Auro Nomizo
MFMaria Cristina Foss-Freitas
Maria Cristina Foss-Freitas
FSFlavia A. Suaid
Flavia A. Suaid
MGMarcio F.M. Grisi
Marcio F.M. Grisi
Background: Periodontitis, a complication of diabetes mellitus (DM), can induce or perpetuate systemic conditions. This double‐masked, placebo‐controlled study evaluated the effects of periodontal therapy (scaling and root planing [SRP]) on the serum levels of glycated hemoglobin (HbA1c) and on inflammatory biomarkers.Methods: Thirty subjects with type 2 DM and periodontitis were treated with SRP + placebo (SRP; N = 15) or with SRP + doxycycline (SRP+Doxy; N = 15), 100 mg/day, for 14 days. Clinical and laboratory data were recorded at baseline and at 3 months after treatment.Results: After 3 months, the reduction in probing depth was 0.8 mm for the SRP group (P <0.01) and 1.1 mm for the SRP+Doxy group (P <0.01) followed by a 0.9% (SRP; P = 0.17) and 1.5% (SRP+Doxy; P <0.01) reduction in HbA1c levels. A significant reduction in interleukin (IL)‐6; interferon‐inducible protein 10; soluble fas ligand; granulocyte colony‐stimulating factor; RANTES; and IL‐12 p70 serum levels were also verified (N = 30). To our knowledge, this is the first report on the effects of periodontal therapy on multiple systemic inflammatory markers in DM.Conclusions: Periodontal therapy may influence the systemic conditions of patients with type 2 DM, but no statistical difference was observed with the adjunctive systemic doxycycline therapy. Moreover, it is possible that the observed improvement in glycemic control and in the reduction of inflammatory markers could also be due to diet, which was not controlled in our study. Therefore, a confirmatory study with a larger sample size and controlled diet is necessary.

1 December 2012 in Gene
Verified
Journal Article
Closed access
FMFernanda S. Manoel-Caetano
Fernanda S. Manoel-Caetano
DXDanilo J. Xavier
Danilo J. Xavier
AEAdriane Evangelista
Adriane Evangelista
PTPaula Takahashi
Paula Takahashi
CCCristhianna V. Collares
Cristhianna V. Collares
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo 

1 April 2014 in Gene
Verified
Journal Article
Closed access
PTPaula Takahashi
Paula Takahashi
DXDanilo J. Xavier
Danilo J. Xavier
AEAdriane Evangelista
Adriane Evangelista
FMFernanda S. Manoel-Caetano
Fernanda S. Manoel-Caetano
CMClaudia Macedo
Claudia Macedo
ESElza Tiemi Sakamoto-Hojo 
Elza Tiemi Sakamoto-Hojo